Evidence map›Paper›PMID 28255364›Full record

ReviewTheranostics2017

Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites.

Xinyue Dong, Dafeng Chu, Zhenjia Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Review
  2. Beyond autologousMolecular therapy. Oncology · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Advances in nanomaterial-based targeted drug delivery systems.Frontiers in bioengineering and biotechnology · 2023
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinyue DongDepartment of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, Washington, USA 99202.
Dafeng ChuDepartment of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, Washington, USA 99202.
Zhenjia WangDepartment of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, Washington, USA 99202.

Funding

Neutrophil-mediated Drug DeliveryR01GM116823 · NIGMS · WASHINGTON STATE UNIVERSITY · PI WANG, ZHENJIA · 2016 to 2020
$1.8M
NIGMS NIH HHS R01 GM116823
6 · The paper itself

Abstract

Nanotechnology has become a powerful tool to potentially translate nanomedicine from bench to bedside. Nanotherapeutics are nanoparticles (NPs) loaded with drugs and possess the property of tissue targeting after surfaces of NPs are bio-functionalized. Designing smaller size of nanotherapeutics is presumed to increase tumor targeting based on the EPR (enhanced permeability and retention) effect. Since the immune systems possess a defence mechanism to fight diseases, there is an emerging concept that NPs selectively target immune cells to mediate the active delivery of drugs into sites of disease. In this review, we will focus on a key question of how nanotherapeutics specifically target immune cells and hijack them as a delivery vehicle to transport nanotherapeutics into disease tissues, thus possibly improving current therapies in inflammation, immune disorders and cancers. We will also discuss the challenges and opportunities for this new strategy of leukocyte-mediated delivery of nanotherapeutics.

Indexed as

Drug Delivery SystemsAnimalsAnti-Inflammatory AgentsAntineoplastic AgentsDrug CarriersHumansInflammationLeukocytesNanoparticlesNeoplasmsAnti-Inflammatory AgentsAntineoplastic AgentsDrug CarriersCancerCirculating leukocytesInflammationLeukocyte infiltration.Nanoparticles

Identifiers

PMID28255364
PMCPMC5327647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.